Crysvita - direct healthcare professional communication (DHPC)

burosumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Crysvita (burosumab): Risk of severe hypercalcaemia

Key facts

• Medicine name:
  Crysvita
• Active substance:
  burosumab
• Therapeutic area (MeSH):
  • Hypophosphatemia, Familial
  • Hypophosphatemic Rickets, X-Linked Dominant
  • Osteomalacia
• Procedure number:
  EMAVR0000261369
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  M05BX05
• Dissemination date:
  09/10/2025